Alaunos Therapeutics (NASDAQ:TCRT) Releases Quarterly Earnings Results

Alaunos Therapeutics (NASDAQ:TCRT) released its quarterly earnings data on Friday. The company reported ($0.59) earnings per share for the quarter, FiscalAI reports.

Alaunos Therapeutics Price Performance

NASDAQ:TCRT opened at $2.47 on Friday. Alaunos Therapeutics has a fifty-two week low of $1.67 and a fifty-two week high of $6.20. The stock has a market capitalization of $5.93 million, a PE ratio of -1.12 and a beta of -1.13. The business’s 50-day simple moving average is $2.93 and its 200-day simple moving average is $3.05.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut Alaunos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, April 29th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has an average rating of “Sell”.

Hedge Funds Weigh In On Alaunos Therapeutics

An institutional investor recently bought a new position in Alaunos Therapeutics stock. HRT Financial LP bought a new stake in Alaunos Therapeutics, Inc. (NASDAQ:TCRT) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 12,602 shares of the company’s stock, valued at approximately $40,000. HRT Financial LP owned about 0.54% of Alaunos Therapeutics as of its most recent filing with the SEC. Institutional investors and hedge funds own 27.72% of the company’s stock.

Alaunos Therapeutics Company Profile

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology.